Limb-girdle muscular dystrophy subtypes: First-reported cohort from northeastern China

Neural Regeneration Research

Volumn 8, Issue 20, 2013, Pages 1907-1918

  Mahmood, Omar Abdulmonem ^a,b   Jiang, Xin Mei ^a   Zhang, Qi ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b UNIVERSITY OF MOSUL   (Iraq)

Author keywords

Calpain 3; Caveolin 3; Dysferlin; Grants supported paper; Limb girdle muscular dystrophy; Neural regeneration; Neuroregeneration; sarcoglycan

Indexed keywords

ACID PHOSPHATASE; ADHALIN; ALPHA SARCOGLYCAN; CALPAIN 3; CAVEOLIN 3; CREATINE KINASE; DYSFERLIN;

ADOLESCENT; ADULT; AGED; ALPHA SARCOGLYCANOPATHY; ARTICLE; CALPAINOPATHY; CAVEOLINOPATHY; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DYSFERLINOPATHY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB WEAKNESS; MACROPHAGE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; MUSCLE BIOPSY; NECROSIS; PHENOTYPE; RETROSPECTIVE STUDY; UPREGULATION; WEAKNESS; WESTERN BLOTTING; YOUNG ADULT;

EID: 84889875719     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.20.010     Document Type: Article

References (68)

1. Nigro V, Aurino S, Piluso G. Limb girdle muscular dystro-phies: update on genetic diagnosis and therapeutic approaches. Curr Opin Neurol. 2011;24(5):429-436.
2. Guglieri M, Magri F, Comi GP. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystro-phies: boundaries and contiguities. Clin Chim Acta. 2005; 361(1-2):54-79.
3. Gallardo E, Saenz A, Illa I. Limb-girdle muscular dystro-phy 2A. Handb Clin Neurol. 2011;101:97-110.
4. Ono Y, Sorimachi H. Calpains: an elaborate proteolytic system. Biochim Biophys Acta. 2012;1824(1):224-236.
5. Ojima K, Ono Y, Ottenheijm C, et al. Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal muscles. J Mol Biol. 2011;407(3):439-449.
6. Angelini C, Nardetto L, Borsato C, et al. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res. 2010;32(1):41-46.
7. Renjini R, Gayathri N, Nalini A, et al. Analysis of calpain-3 protein in muscle biopsies of different muscular dystro-phies from India. Indian J Med Res. 2012;135(6):878-886.
8. Comerlato EA, Scola RH, Werneck LC. Limb-girdle mus-cular dystrophy: an immunohistochemical diagnostic approach. Arq Neuropsiquiatr. 2005;63(2A):235-245.
9. Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B, et al. Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve. 2012;45(3):338-345.
10. Luo SS, Xi JY, Lu JH, et al. Clinical and pathological features in 15 Chinese patients with calpainopathy. Muscle Nerve. 2011;43(3):402-409.
11. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20(1):31-36.
12. Amato AA, Brown RH Jr. Dysferlinopathies. Handb Clin Neurol. 2011;101:111-118.
13. Gáti I, Danielsson O, Gunnarsson C, et al. Bent spine syndrome: a phenotype of dysferlinopathy or a symptomatic DYSF gene mutation carrier. Eur Neurol. 2012;67(5): 300-302.
14. Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75(4):316-323.
15. Ho M, Gallardo E, McKenna-Yasek D, et al. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol. 2002; 51(1):129-133.
16. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168-172.
17. Cacciottolo M, Numitone G, Aurino S, et al. Muscular dy-strophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur J Hum Genet. 2011;19(9):974-980.
18. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlino-pathies. Hum Mutat. 2005;26(2):165.
19. Cagliani R, Magri F, Toscano A, et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dy-strophies. Hum Mutat. 2005;26(3):283.
20. Kawabe K, Goto K, Nishino I, et al. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol. 2004;11(10):657-661.
21. Roberds SL, Leturcq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell. 1994;78(4):625-633.
22. Minetti C, Sotgia F, Bruno C, et al. Mutations in the cave-olin-3 gene cause autosomal dominant limb-girdle mus-cular dystrophy. Nat Genet. 1998;18(4):365-368.
23. Lo HP, Cooper ST, Evesson FJ, et al. Limb-girdle muscu-lar dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord. 2008;18(1):34-44.
24. Dinçer P, Leturcq F, Richard I, et al. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol. 1997;42(2): 222-229.
25. Urtasun M, Sáenz A, Roudaut C, et al. Limb-girdle mus-cular dystrophy in Guipúzcoa (Basque Country, Spain). Brain. 1998;121 (Pt 9):1735-1747.
26. Pogoda TV, Krakhmaleva IN, Lipatova NA, et al. High incidence of 550delA mutation of CAPN3 in LGMD2 pa-tients from Russia. Hum Mutat. 2000;15(3):295.
27. Zatz M, de Paula F, Starling A, et al. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord. 2003;13(7-8):532-544.
28. Fanin M, Nascimbeni AC, Aurino S, et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology. 2009;72(16):1432-1435.
29. Guglieri M, Magri F, D'Angelo MG, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat. 2008;29(2):258-266.
30. Stensland E, Lindal S, Jonsrud C, et al. Prevalence, mutation spectrum and phenotypic variability in Norwegian patients with Limb Girdle Muscular Dystrophy 2I. Neuro-muscul Disord. 2011;21(1):41-46.
31. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol. 2006;59(5): 808-815.
32. Meena AK, Sreenivas D, Sundaram C, et al. Sarcoglyca-nopathies: a clinico-pathological study. Neurol India. 2007;55(2):117-121.
33. Gayathri N, Alefia R, Nalini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tis-sue. Indian J Pathol Microbiol. 2011;54(2):350-354.
34. Moore SA, Shilling CJ, Westra S, et al. Limb-girdle mus-cular dystrophy in the United States. J Neuropathol Exp Neurol. 2006;65(10):995-1003.
35. Hayashi S, Ohsawa Y, Takahashi T, et al. Rapid screening for Japanese dysferlinopathy by fluorescent primer exten-sion. Intern Med. 2010;49(24):2693-2696.
36. Sáenz A, Leturcq F, Cobo AM, et al. LGMD2A: geno-type-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain. 2005;128(Pt 4):732-742.
37. Ren SC, Yan CZ, Li MX, et al. Dysferlin expression in limb-girdle muscular dystrophy and Miyoshi myopathy: analysis of 45 cases. Zhonghua Yi Xue Za Zhi. 2007; 87(21):1486-1490.
38. Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain. 1996;119 (Pt 1):295-308.
39. Fanin M, Fulizio L, Nascimbeni AC, et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat. 2004;24(1):52-62.
40. Fanin M, Nascimbeni AC, Tasca E, et al. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Eur J Hum Genet. 2009;17(5):598-603.
41. Groen EJ, Charlton R, Barresi R, et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain. 2007;130(Pt 12):3237-3249.
42. Herrmann R, Straub V, Blank M, et al. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum Mol Genet. 2000;9(15):2335-2340.
43. Boito C, Fanin M, Siciliano G, et al. Novel sarcoglycan gene mutations in a large cohort of Italian patients. J Med Genet. 2003;40(5):e67.
44. Higuchi I, Kawai H, Umaki Y, et al. Different manners of sarcoglycan expression in genetically proven alpha-sarc-oglycan deficiency and gamma-sarcoglycan deficiency. Acta Neuropathol. 1998;96(2):202-206.
45. Trabelsi M, Kavian N, Daoud F, et al. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet. 2008;16(7):793-803.
46. Klinge L, Dekomien G, Aboumousa A, et al. Sarcoglyca-nopathies: can muscle immunoanalysis predict the geno-type? Neuromuscul Disord. 2008;18(12):934-941.
47. Fanin M, Nascimbeni AC, Fulizio L, et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord. 2005;15(3):218-224.
48. Ueyama H, Kumamoto T, Horinouchi H, et al. Clinical heterogeneity in dysferlinopathy. Intern Med. 2002;41(7): 532-536.
49. Hicks D, Sarkozy A, Muelas N, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dy-strophy. Brain. 2011;134(Pt 1):171-182.
50. Nalini A, Gayathri N. Dysferlinopathy: a clinical and his-topathological study of 28 patients from India. Neurol India. 2008;56(3):379-387.
51. Park HJ, Hong JM, Suh GI, et al. Heterogeneous charac-teristics of Korean patients with dysferlinopathy. J Korean Med Sci. 2012;27(4):423-429.
52. Liewluck T, Pongpakdee S, Witoonpanich R, et al. Novel DYSF mutations in Thai patients with distal myopathy. Clin Neurol Neurosurg. 2009;111(7):613-618.
53. Kawai H, Akaike M, Kunishige M, et al. Clinical, patholog-ical, and genetic features of limb-girdle muscular dystro-phy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. Muscle Nerve. 1998;21(11):1493-1501.
54. Passos-Bueno MR, Vainzof M, Moreira ES, et al. Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. Am J Med Genet. 1999;82(5):392-398.
55. Nagaraju K, Rawat R, Veszelovszky E, et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol. 2008;172(3):774-785.
56. Drosos AA, Dalakas MC. Identification of macrophages in the muscle biopsy preparations: a comparative study using spe-cific monoclonal antimacrophage antibodies and acid phos-phatase reaction. Muscle Nerve. 1995;18(2):242-244.
57. Confalonieri P, Oliva L, Andreetta F, et al. Muscle inflam-mation and MHC class I up-regulation in muscular dy-strophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142(1-2):130-136.
58. Hauerslev S, Sveen ML, Duno M, et al. Calpain 3 is im-portant for muscle regeneration: evidence from patients with limb girdle muscular dystrophies. BMC Musculoskelet Disord. 2012;13:43.
59. Han R. Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle. 2011;1(1):10.
60. de Paula F, Vainzof M, Bernardino AL, et al. Mutations in the caveolin-3 gene: When are they pathogenic? Am J Med Genet. 2001;99(4):303-307.
61. th Annual Dysferlin Conference 11-14 July 2011, Chicago, Illinois, USA. Neuromuscul Disord. 2012;22(5):471-477.
62. Lostal W, Bartoli M, Bourg N, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet. 2010;19(10): 1897-1907.
63. State Council of the People's Republic of China. Adminis-trative Regulations on Medical Institution. 1994-09-01.
64. Bennett HS, Wyrick AD, Lee SW, et al. Science and art in preparing tissues embedded in plastic for light microscopy, with special reference to glycol methacrylate, glass knives and simple stains. Stain Technol. 1976;51(2):71-97.
65. Ramos-Vara JA. Technical aspects of immunohistoche-mistry. Vet Pathol. 2005;42(4):405-426.
66. Mathews ST, Plaisance EP, Kim T. Imaging systems for westerns: chemiluminescence vs. infrared detection. Me-thods Mol Biol. 2009;536:499-513.
67. Takahashi T, Aoki M, Suzuki N, et al. Clinical features and a mutation with late onset of limb girdle muscular dystro-phy 2B. J Neurol Neurosurg Psychiatry. 2013;84(4):433-440.
68. Angelini C, Peterle E, Gaiani A, et al. Dysferlinopathy course and sportive activity: clues for possible treatment. Acta Myol. 2011;30(2):127-132.